How do recent RxPonder results affect your adjuvant therapy choice for premenopausal women with HR+/HER2 negative breast cancer with 1-3 positive LNs?

Topics: Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Iowa • HR+ • NCI-CCC Breast Tumor Board Question

Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?

Answer from: Medical Oncologist at Academic Institution

In the RxPONDER clinical trial, all premenopausal patients with HR+ HER2-negative breast cancer with 1-3 positive LNs had a benefit from adjuvant chemotherapy regardless of their Oncotype DX RS. Therefore, there would not be a need to send for an Oncotype or Mammaprint. This management would not cha...

Comments

Medical Oncologist at Gerard J Ventura MD, FACP
At least for premenopausal patients, the data seem...

Medical Oncologist
What is the interpretation of LN micro metastasis ...

Related Questions